FOLH1 and posterior cortical atrophy: Both prostate-specific membrane antigen (PSMA) PET/CT and ferumoxtran-10 nanoparticle–enhanced MRI (nano-MRI) are imaging modalities with high potential to identify LN metastases in PCa patients.